Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

Stéphane de Botton,Karen W.L. Yee,Christian Recher,Andrew Wei,Pau Montesinos,David Taussig,Arnaud Pigneux,Thorsten Braun,Antonio Curti,Jordi Esteve,Carolyn S. Grove,Brian A. Jonas,Asim Khwaja,Ollivier Legrand,Pierre Peterlin,Olga Polyanskaya,Jennifer Sweeney,Hesham Mohamed,Jorge E. Cortes,Pierre Fenaux

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

2021

7006Background: Olutasidenib, a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1), has exhibited favorable tolerability and clinical activity in high-risk AML patients (pts) ...

Keywords:

Internal medicine
Medicine
Tolerability
Oncology
in patient
Phases of clinical research
Interim analysis
Myeloid leukemia
relapsed refractory
IDH1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations